title: Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
authors.forename: Estelle
authors.initials: E
authors.lastname: Rose
authors.forename: Thierry
authors.initials: T
authors.lastname: Lequerré
authors.forename: Sophie
authors.initials: S
authors.lastname: Pouplin
authors.forename: Alain
authors.initials: A
authors.lastname: Daragon
authors.forename: Xavier
authors.initials: X
authors.lastname: Le Loët
authors.forename: Olivier
authors.initials: O
authors.lastname: Vittecoq
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D016527:Drug Costs; D057915:Drug Substitution / Q000191:economics*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept